@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev
@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce
@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce
> Boston Scientific ($BSX) hired a veteran Abiomed ($ABMD) executive to be its new vice president of investor relations. Item
> Fisher & Paykel Healthcare, a New Zealand medical equipment manufacturer, reported record profit and higher revenues for the first half of its fiscal year. Item
> NeuroMetrix ($NURO) debuted a new website designed to help convey information to physicians and patients about chronic pain and the company's signature nerve stimulation device designed to address it. Item
> Finland's BonAlive Biomaterials gained a CE mark for the new ready-to-use moldable version of its osteostimulative bioactive glass bone regeneration putty. Item
> OrthoSensor will use Valtronic to manufacture its Verasense intelligent knee system. Item
> Observers are getting anxious about final efforts to revamp Europe's medical device regulations. Item
Biotech News
@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech
@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce
@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce
@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce
> Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug. Story
> Novartis sneaks up on Pfizer with CDK4/6 cancer challenger. Article
> Food allergy startup bags $17M for oral immunotherapy. News
Pharma News
@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma
@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce
@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce
> Ariad's Iclusig further restricted by EMA. Story
> Novartis plans $5B share buyback, hints at restructuring. Article
> EU patent call sets stage for Tecfidera launch in Europe. Report